ClinicalTrials.gg
CompletedNCT04712734Updated Jun 29, 2023

A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia

A Phase 1 interventional study of Iloperidone in Schizophrenia, sponsored by Vanda Pharmaceuticals. Completed at 3 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-06-29.

Sponsored by Vanda Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2022, 4 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing iloperidone in Schizophrenia — 2 open to participants now, 2 under way, 1 of them phase 3. iloperidone · Schizophrenia.

Enrollment
8th of 11
42 · median 260
Started
2021
the only one that year
Phase 1
3 of 11
none open now
Registered
9th of 11
by date
Lead sponsor
7 of 11
Vanda Pharmaceuticals

Among the 11 studies testing iloperidone in Schizophrenia, this one is the 8th largest by enrollment, is the only one that started in 2021, is one of 3 in phase 1, and was the 9th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 11 studies testing iloperidone in Schizophrenia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About iloperidone

iloperidone: first FDA approval 2009 (FANAPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing iloperidone in Schizophrenia, or all of them as a file.
02

Study summary

This is a multicenter, open-label, adaptive, repeat-dose study to evaluate the safety, tolerability, and pharmacokinetics of iloperidone long-acting injection (LAI) in patients with schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to provide written .
  • Male or female patients 18 to 65 years of age (inclusive).
  • Clinical diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorder () for at least 1 year.
  • Symptomatically stable within the past two months.

Exclusion criteria

Exclusion Criteria:

  • Use of other drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer.
  • Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs.
  • Pregnant or nursing (lactating) women.
  • A positive test for drugs of abuse.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Iloperidone

    Drug: Iloperidone

Interventions

  • oral tablet, long-acting injection

    Also known as: VYV-683

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics of iloperidone and its metabolites following repeat-dosing of iloperidone given as a long-acting injection.

    As measured by plasma concentrations.

    Time frame: 24 weeks

  2. Assessment of safety and tolerability of repeat-dosing of iloperidone given as a long-acting injection.

    As measured by spontaneous reporting of adverse events (AEs).

    Time frame: 24 weeks

07

Study locations

3 sites
  • Vanda Investigational Site
    Garden Grove, California 92845, United States
  • Vanda Investigational Site
    Gaithersburg, Maryland 20877, United States
  • Vanda Investigational Site
    Marlton, New Jersey 08053, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Aug 2022, 19 months.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 19 months is above that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2021
First posted
Jan 15, 2021
StartActual
Jan 13, 2021
Primary completionActual
Aug 30, 2022
CompletionActual
Aug 30, 2022
Last update
Jun 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04712734
Responsible party
Sponsor
First posted
Jan 15, 2021
Start date
Jan 13, 2021
Primary completion
Aug 30, 2022
Completion
Aug 30, 2022
Last update
Jun 29, 2023

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Iloperidone

Start the discussion